These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21691281)

  • 41. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
    BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy.
    Cremers RG; van Lin EN; Gerrits WL; van Tol-Geerdink JJ; Kiemeney LA; Vergunst H; Smans AJ; Kaanders JH; Alfred Witjes J
    Radiother Oncol; 2010 Dec; 97(3):467-73. PubMed ID: 20817287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study.
    Fossati N; Robesti D; Karnes RJ; Soligo M; Boorjian SA; Bossi A; Coraggio G; Di Muzio N; Cozzarini C; Noris Chiorda B; Gandaglia G; Scarcella S; Bartkowiak D; Böhmer D; Shariat S; Goldner G; Battaglia A; Joniau S; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Wiegel T; Briganti A
    Eur Urol; 2019 Oct; 76(4):443-449. PubMed ID: 30799187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.
    Brooks JP; Albert PS; Wilder RB; Gant DA; McLeod DG; Poggi MM
    J Urol; 2005 Dec; 174(6):2204-8, discussion 2208. PubMed ID: 16280764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Hawken SR; Spratt DE; Qi J; Linsell SM; Cher ML; Ghani KR; Miller DC; Montie JE; Morgan TM;
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1030-1034. PubMed ID: 30682490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
    Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
    Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.
    Ross AE; Den RB; Yousefi K; Trock BJ; Tosoian J; Davicioni E; Thompson DJ; Choeurng V; Haddad Z; Tran PT; Trabulsi EJ; Gomella LG; Lallas CD; Abdollah F; Feng FY; Klein EA; Dicker AP; Freedland SJ; Karnes RJ; Schaeffer EM
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):277-82. PubMed ID: 27136742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant radiation treatment after prostatectomy. Where do we stand?
    Elshaikh MA; Ibrahim DR; Stricker H; Peabody JO
    Can J Urol; 2011 Apr; 18(2):5592-600. PubMed ID: 21504646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
    Reed SD; Stewart SB; Scales CD; Moul JW
    Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy.
    Budiharto T; Perneel C; Haustermans K; Junius S; Tombal B; Scalliet P; Renard L; Lerut E; Vekemans K; Joniau S; Van Poppel H
    Radiother Oncol; 2010 Dec; 97(3):474-9. PubMed ID: 20950879
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
    Tay KJ; Polascik TJ; Howard LE; Salama JK; Schulman AA; Chen Z; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Clin Genitourin Cancer; 2019 Oct; 17(5):e930-e938. PubMed ID: 31257075
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
    Zubek VB; Konski A
    Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.